ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
Jun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
Aug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
Sep 20, 2024 · Sanofi continues to advance SARCLISA as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications.
Sanofi wins US approval for multiple myeloma drug in newly …
Sep 20, 2024 · The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed...
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved …
Aug 8, 2024 · On Thursday, Sanofi SA (NASDAQ: SNY) reported new results from the GMMG-HD7 phase 3 study of Sarclisa in combination with lenalidomide, bortezomib, and dexamethasone (RVd) versus RVd induction...
FDA approves Sarclisa with bortezomib, lenalidomide, and …
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly...
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
Sep 23, 2024 · The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib, lenalidomide, and dexamethasone (VRd), for...
Sanofi builds case for Sarclisa, challenging J&J’s Darzalex
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple …
Sep 23, 2024 · Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination...
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer ...
Sep 20, 2024 · Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for ...
- Some results have been removed